Table 2.
Characteristics of the study population.
| Characteristics | Flagged patients (n=2933) | Invited patients (n=1636) | Participating patients (n=295)a | ||||
| Female, n (%) | 1741 (59.36) | 958 (58.56) | 141 (47.77) | ||||
| Age (years), mean (SD) | 63.46 (19.05) | 62.91 (17.89) | 66.4 (12.91) | ||||
| Age (years), n (%) | |||||||
|
|
18-44 | 549 (18.72) | 282 (17.24) | 19 (6.42) | |||
|
|
45-64 | 758 (25.84) | 457 (27.93) | 95 (32.32) | |||
|
|
65-74 | 652 (22.23) | 423 (25.86) | 111 (37.58) | |||
|
|
75-84 | 620 (21.14) | 334 (20.42) | 54 (18.32) | |||
|
|
≥85 | 354 (12.07) | 140 (8.56) | 16 (5.43) | |||
| Use of overactive bladder medication, n (%)b,c | 640 (22.42) | 392 (24.87) | 68 (25.78) | ||||
| Number of chronic diseases, n (%)b,d | |||||||
|
|
0 | 405 (20.94) | 203 (20.34) | 31 (16.93) | |||
|
|
1 or 2 | 725 (27.48) | 421 (42.18) | 80 (43.69) | |||
|
|
≥3 | 804 (41.57) | 374 (37.47) | 72 (39.31) | |||
aResults of the 7 patients who did not give consent for data linkage between questionnaires and electronic health record data were not included in calculations on overactive bladder medication and number of chronic diseases.
bInformation on medication use was available for 2854, 1576, and 264 patients, and information on chronic comorbidities was available for 1934, 998, and 183 patients.
cOveractive bladder medication was defined as medication with Anatomical Therapeutic Chemical code G04BD.
dThe number of chronic comorbidities was based on a list of the 29 most common chronic diseases, including, for example, Chronic Obstructive Pulmonary Disease and cardiovascular disease [15].